Mt. Jackson, VA – April 4, 2025: StageBio is bringing a presence to this year’s Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Pathologists representing StageBio at the event bring their extensive experience in the evaluation of ophthalmic drugs, animal models, ocular dosing routes, and ocular medical devices.

StageBio invites those attending ARVO 2025 to visit booth #1539 for discussions with our team on the latest in ocular pathology.

The ARVO Annual Meeting brings eye and vision scientists together to share research findings, announce treatment breakthroughs, and collaborate in an environment designed to encourage the free exchange of ideas.

ARVO 2025 will take place May 4-8 in Salt Lake City, Utah. This year’s event will focus on the impact of new technologies – like the exponential increase of computing power and the continued maturity of artificial intelligence – on treating, curing, and preventing eye disease. CRISPR and mRNA technologies, virtual reality, and advancements in gene therapy are only a few of the topics that will be covered.

For more information regarding the preclinical and clinical capabilities services of StageBio, contact us at www.stagebio.com/contact. 

About StageBio

StageBio is a leading provider of GLP-compliant necropsy, histology, pathology and specimen archiving services for the biopharmaceutical, medical device, academic, government and contract research industries. The company operates four GLP laboratories as well as two GLP specimen archiving facilities in the U.S. and Europe, with substantial continued investment in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 25 board-certified veterinary pathologists and more than 100 laboratory personnel on staff supporting our unified commitment to quality, scientific integrity and client satisfaction. Learn more at www.stagebio.com.